Repairing the damage to nerves caused by MS is possible, according to new research.
A study of the cancer drug bexarotene in Cambridge and Edinburgh showed that it led to the regrowth of myelin in people with relapsing remitting MS. However, the dose needed to produce this effect also led to serious side effects including thyroid disease and potentially damaging levels of blood fats. The results were presented at the MS Virtual conference.
Although the fact that it is possible to encourage the regrowth if myelin in humans is a breakthrough and will leads to further research, the side effects mean that bexarotene will not become a treatment for MS.
Covid-19 vaccines and MS
12 Nov 2020 - 00:00
We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.
A round-up of research from MS Virtual 2020
4 Nov 2020 - 00:00
An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference.
Siponimod (Mayzent) approved for active secondary progressive MS in England and Wales
15 Oct 2020 - 00:00
The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.
MS in the Media
27 Nov 2020 - 00:00
- Depression affects multitasking in MS
- Benefits process in Scotland
- Cancer risks and multiple sclerosis
- Gut immune cells and relapses
MS in the Media
20 Nov 2020 - 00:00
- New study for advanced MS
- Campaign for fair benefits during the pandemic
- Stem cells compared to Lemtrada
- DMD use and finances
David Martin appointed Chair of the Neurological Alliance
18 Nov 2020 - 00:00
The MS Trust is delighted to announce that CEO David Martin, has been voted in as Chair of the Neurological Alliance.